In vivo synergism of ceftobiprole and vancomycin against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 9, 2011, Pages 3977-3984

  Entenza, J M ^a   Veloso, T R ^a   Vouillamoz, J ^a   Giddey, M ^a   Majcherczyk, P ^a   Moreillon, P ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTOBIPROLE; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; IN VIVO STUDY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RAT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DRUG SYNERGISM; ENDOCARDITIS; FEMALE; MICROBIAL SENSITIVITY TESTS; RATS; RATS, WISTAR; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 80051824372     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00402-11     Document Type: Article

References (47)

1. Aritaka, N., H. Hanaki, L. Cui, and K. Hiramatsu. 2001. Combination effect of vancomycin and beta-lactams against a Staphylococcus aureus strain, Mu3, with heterogeneous resistance to vancomycin. Antimicrob. Agents Chemother. 45:1292-1294. (Pubitemid 32232984)
2. Blouin, R A, L A Bauer, D D Miller, K E Record, and W O Griffen, Jr. 1982. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob. Agents Chemother. 21:575-580. (Pubitemid 12070524)
3. Bush, K., M. Heep, M J Macielag, and G J Noel. 2007. Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: The first anti-MRSA beta-lactam to demonstrate clinical efficacy. Expert Opin. Invest. Drugs 16:419-429. (Pubitemid 46554461)
4. Chambers, H F 2005. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin- intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 49:884-888. (Pubitemid 40327700)
5. Chambers, H F, and M. Sachdeva. 1990. Binding of beta-lactam antibiotics to penicillin-binding proteins in methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 161:1170-1176. (Pubitemid 20177877)
6. Climo, M W, R L Patron, and G L Archer. 1999. Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin. Antimicrob. Agents Chemother. 43:1747-1753. (Pubitemid 29331259)
7. CLSI. 2006. Performance standards for antimicrobial susceptibility testing, 16th ed. Approved standard M100-S16. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Cosgrove, S E, and V G Fowler, Jr. 2008. Management of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46(Suppl. 5):S386-S393. (Pubitemid 351717326)
9. Cremieux, A C, et al. 1989. Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography. J. Infect. Dis. 159:938-944.
10. Cui, L., E. Tominaga, H M Neoh, and K. Hiramatsu. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:1079-1082. (Pubitemid 43327815)
11. Davies, T A, et al. 2007. Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51:2621-2624. (Pubitemid 47047351)
12. De Jonge, B L, Y S Chang, D. Gage, and A. Tomasz. 1992. Peptidoglycan composition in heterogeneous Tn551 mutants of a methicillin-resistant Staphylococcus aureus strain. J. Biol. Chem. 267:11255-11259.
13. Domaracki, B E, A M Evans, and R A Venezia. 2000. Vancomycin and oxacillin synergy for methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 44:1394-1396. (Pubitemid 30228332)
14. Domenech, A., et al. 2005. Experimental study on the efficacy of combinations of glycopeptides and beta-lactams against Staphylococcus aureus with reduced susceptibility to glycopeptides. J. Antimicrob. Chemother. 56:709-716. (Pubitemid 41487773)
15. Entenza, J M, P. Hohl, I. Heinze-Krauss, M P Glauser, and P. Moreillon. 2002. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob. Agents Chemother. 46:171-177. (Pubitemid 34031620)
16. Falagas, M E, K G Manta, F. Ntziora, and K Z Vardakas. 2006. Linezolid for the treatment of patients with endocarditis: A systematic review of the published evidence. J. Antimicrob. Chemother. 58:273-280. (Pubitemid 44313381)
17. Fernandez, J., et al. 2010. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr. B-061.
18. Fluckiger, U., et al. 1994. Simulation of amoxicillin pharmacokinetics in humans for the prevention of streptococcal endocarditis in rats. Antimicrob. Agents Chemother. 38:2846-2849. (Pubitemid 24374446)
19. Fowler, V G, Jr., et al. 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355:653-665.
20. Franciolli, M., J. Bille, M P Glauser, and P. Moreillon. 1991. Beta-lactam resistance mechanisms of methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 163:514-523.
21. Garau, J., E. Bouza, J. Chastre, F. Gudiol, and S. Harbarth. 2009. Management of methicillin-resistant Staphylococcus aureus infections. Clin. Microbiol. Infect. 15:125-136.
22. Goldstein, F W, et al. 2004. False synergy between vancomycin and betalactams against glycopeptide-intermediate Staphylococcus aureus (GISA) caused by inappropriate testing methods. Clin. Microbiol. Infect. 10:342-345. (Pubitemid 38519365)
23. Guignard, B., J M Entenza, and P. Moreillon. 2005. Beta-lactams against methicillin-resistant Staphylococcus aureus. Curr. Opin. Pharmacol. 5:479-489. (Pubitemid 41258564)
24. Hebeisen, P., et al. 2001. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin- resistant staphylococci. Antimicrob. Agents Chemother. 45:825-836. (Pubitemid 32182033)
25. Heraief, E., M P Glauser, and L R Freedman. 1982. Natural history of aortic valve endocarditis in rats. Infect. Immun. 37:127-131. (Pubitemid 12095191)
26. Hiramatsu, K., et al. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136. (Pubitemid 27341646)
27. Howden, B P, J K Davies, P D Johnson, T P Stinear, and M L Grayson. 2010. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: Resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 23:99-139.
28. Howe, R A, M. Wootton, P M Bennett, A P MacGowan, and T R Walsh. 1999. Interactions between methicillin and vancomycin in methicillin-resistant Staphylococcus aureus strains displaying different phenotypes of vancomycin susceptibility. J. Clin. Microbiol. 37:3068-3071. (Pubitemid 29391946)
29. Jacqueline, C., et al. 2011. Comparison of ceftaroline fosamil, daptomycin and tigecycline in an experimental rabbit endocarditis model caused by methicillin-susceptible, methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. J. Antimicrob. Chemother. 66:863-866.
30. Katayama, Y., H Z Zhang, and H F Chambers. 2004. PBP 2a mutations producing very-high-level resistance to beta-lactams. Antimicrob. Agents Chemother. 48:453-459. (Pubitemid 38141701)
31. Majcherczyk, P A, et al. 1999. Digestion of Streptococcus pneumoniae cell walls with its major peptidoglycan hydrolase releases branched stem peptides carrying proinflammatory activity. J. Biol. Chem. 274:12537-12543.
32. Moreillon, P, and Y A Que. 2004. Infective endocarditis. Lancet 363:139-149. (Pubitemid 38068333)
33. Page, M G 2006. Anti-MRSA beta-lactams in development. Curr. Opin. Pharmacol. 6:480-485.
34. Patel, J B, L A Jevitt, J. Hageman, L C McDonald, and F C Tenover. 2006. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin. Infect. Dis. 42:1652-1653.
35. Pinho, M G, H. De Lencastre, and A. Tomasz. 2001. An acquired and a native penicillin-binding protein cooperate in building the cell wall of drug-resistant staphylococci. Proc. Natl. Acad. Sci. U. S. A. 98:10886-10891. (Pubitemid 32878714)
36. Rochon-Edouard, S., M. Pestel-Caron, J F Lemeland, and F. Caron. 2000. In vitro synergistic effects of double and triple combinations of beta-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains. Antimicrob. Agents Chemother. 44:3055-3060.
37. Sader, H S, and R N Jones. 2006. The activity of daptomycin against wild-type Staphylococcus aureus and strains with reduced susceptibility to vancomycin. Clin. Infect. Dis. 43:798-799. (Author reply, 43:799-800.)
38. Sakoulas, G., Y. Golan, K C Lamp, L V Friedrich, and R. Russo. 2007. Daptomycin in the treatment of bacteremia. Am. J. Med. 120:S21-S27. (Pubitemid 47464124)
39. Saravolatz, L D, J. Pawlak, L B Johnson, L D Saravolatz, 2nd, and N. Husain. 2010. In vitro activity of ceftobiprole against meticillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA). Int. J. Antimicrob. Agents 36:478-480.
40. Schmitt-Hoffmann, A., et al. 2004. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob. Agents Chemother. 48:2576-2580. (Pubitemid 38823427)
41. Schmitt-Hoffmann, A., et al. 2004. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob. Agents Chemother. 48:2570-2575. (Pubitemid 38823426)
42. Sieradzki, K., R B Roberts, S W Haber, and A. Tomasz. 1999. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N. Engl. J. Med. 340:517-523. (Pubitemid 29093287)
43. Sieradzki, K, and A. Tomasz. 1997. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J. Bacteriol. 179:2557-2566. (Pubitemid 27164554)
44. Snowden, M A, and H R Perkins. 1990. Peptidoglycan cross-linking in Staphylococcus aureus. An apparent random polymerisation process. Eur. J. Biochem. 191:373-377. (Pubitemid 20233751)
45. Tattevin, P., L. Basuino, D. Bauer, B A Diep, and H F Chambers. 2010. Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 54:610-613.
46. Vouillamoz, J., J M Entenza, C. Feger, M P Glauser, and P. Moreillon. 2000. Quinupristin-dalfopristin combined with beta-lactams for treatment of experimental endocarditis due to Staphylococcus aureus constitutively resistant to macrolide-lincosamide-streptogramin B antibiotics. Antimicrob. Agents Chemother. 44:1789-1795. (Pubitemid 30422926)
47. Zhao, G., T I Meier, S D Kahl, K R Gee, and L C Blaszczak. 1999. BOCILLIN FL, a sensitive and commercially available reagent for detection of penicillin-binding proteins. Antimicrob. Agents Chemother. 43:1124-1128. (Pubitemid 29214735)